Devices, methods, and compositions useful in cryo-preservation, -storage, -transport, and application of therapeutic mammalian cells
Improved cryopreservation compositions and devices using a freezing medium, agent, and organic polymers maintain mammalian cell viability and sterility during freezing and storage, addressing contamination and manipulation issues, ensuring high post-thaw viability and efficacy.
Patent Information
- Application Number
- JP2024151958
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2017-03-02
- Filing Date
- 2024-09-04
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2038-03-02
AI Technical Summary
Conventional cryopreservation methods for mammalian cells result in variable post-thawing viability, require additional manipulation, and pose risks of contamination and disease transmission due to animal serum use, necessitating improved compositions and methods for freezing and storage.
Compositions including a freezing medium, freezing agent (e.g., dimethyl sulfoxide), and organic polymers (e.g., hyaluronic acid) maintain cell viability and sterility during freezing, storage, and administration, using containers made from biocompatible materials that minimize manipulation and reduce contamination.
The compositions and devices ensure high post-thaw viability (50-100%) with reduced manipulation, maintaining sterility and efficacy, and enable direct administration to patients without significant loss of cell integrity.
Smart Images

Figure 2024167383000006 
Figure 2024167383000007 
Figure 2024167383000008
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 62 / 466,228, filed March 2, 2017, entitled “Devices, Methods, And Compositions Useful in Cryo-Preservation Mammalian Cells,” which is incorporated by reference in its entirety.
[0002] Field The disclosed processes, methods and systems relate to the storage of mammalian cells for medical treatment at very low temperatures for extended periods of time without significant loss of viability, such that upon thawing, such cells may be administered to a patient with little or no manipulation. [Background technology]
[0003] Therapeutic cells are either obtained directly from a mammalian donor or after selection, enrichment, expansion, etc. in cell culture and then administered to a patient. In some cases, the therapeutic cells may be stored or transported prior to administration. To maintain cell viability during storage and / or transport, the therapeutic cells may be frozen at very low temperatures to preserve and protect their therapeutic potential (cryopreservation or cryopreservation). This cryopreservation may allow for long-term storage and / or long-term transport with little or no loss of therapeutic efficacy.
[0004] Conventional cryopreservation methods can result in inconsistent or low post-thaw viability of cells for treatment, and further require additional handling and manipulation to transfer the cells to an apparatus or device for administration and / or to remove one or more cryopreservation substances.
[0005] Subsequent manipulation of the therapeutic cells can adversely affect their integrity, viability and efficacy. Furthermore, transferring the therapeutic cells to a suitable medical device or apparatus increases the risk of contamination of the cells with unwanted bacteria, viruses, chemicals, etc. In addition, traditional freezing methods that rely on the use of animal serum can expose the human recipient to the risk of contracting animal-borne diseases.
[0006] Thus, there is a need for improved compositions and methods for use in freezing cells for treatment, as well as means for reducing post-thaw handling. Summary of the Invention
[0007] Disclosed is a composition for cryopreservation and preservation of eukaryotic cells in a pharmaceutical composition for treatment. The composition of the present invention comprises a freezing medium, a cryogen (e.g., dimethyl sulfoxide), and one or more organic polymers (e.g., hyaluronic acid). The composition of the present invention also allows freezing of cells for treatment with or without animal serum. The composition and device of the present disclosure can maintain cell viability and sterility through freezing of cells, long-term storage at -130°C to -196°C, thawing, and administration to a patient.
[0008] Further disclosed are containers useful in freezing and thawing eukaryotic cells. In many embodiments, the containers of the present invention are suitable for administration of cells after thawing, requiring little or no manipulation of the cell mixture prior to administration. In many embodiments, the containers of the present invention define at least a portion of a medical device, such as a syringe, where the container can maintain the sterility of the cell mixture during freezing and thawing and can be used to administer the mixture to a patient in need thereof. The containers of the present invention can include a lumen and first and second open ends, which can be configured to receive a cap, tip, plug, plunger, or other structure suitable for containing the mixture within the lumen. The containers of the present invention are manufactured from a biocompatible material that maintains its integrity throughout the freezing and thawing process.
[0009] Disclosed herein are devices, compositions and methods for use in maintaining the viability of therapeutic mammalian cells at low temperatures, and the disclosed devices are also useful in reducing cell manipulation prior to administration to a patient in need thereof. The disclosed compositions, devices and methods maintain cell viability, thus helping to reduce loss of therapeutic efficacy.
[0010] Additional objects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or will become apparent by the practice of the invention. The objects and advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. [Brief description of the drawings]
[0011] [Figure 1] 1 shows one embodiment of a device for freezing, storing and applying cell compositions of the present disclosure. The top figure shows the various parts of the device unassembled. The bottom figure shows a cross-sectional view of the device. [Diagram 2] FIG. 2 illustrates one embodiment of an assembled device of the present disclosure configured to reduce contamination during freezing, storage, transportation, and thawing of a composition of the present disclosure contained within a barrel lumen. [Diagram 3] Figure 3 shows a comparison of recovery and viability after one month of storage in the vapor phase of liquid nitrogen using various media with 1% hyaluronic acid. The freezing container used in the experiment was a syringe system. Good recovery and viability were observed with all media. [Figure 4] Figure 4 shows a bar graph of the non-destructive measurement of headspace oxygen for DiscGenics syringe samples. The values of headspace oxygen concentration change between time points T0 and T1 are shown. Headspace oxygen concentrations at both time points were treated as the average of five replicate measurements for each syringe. The red horizontal line indicates a 3.0% decrease in oxygen, which was used as the criterion for loss of container closure integrity for the syringes. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] The present invention provides compositions and methods for freezing eukaryotic cells (e.g., mammalian cells) at very low temperatures for storage and / or transportation. In addition, medical devices and apparatuses are provided that are useful for containing the frozen cells and reduce the manipulation of the cells prior to subsequent administration. In addition, methods of freezing and storing the compositions of the present disclosure in the devices of the present disclosure are also disclosed. Here, the freezing and storage methods provide surprisingly improved resistance to contamination by gases, liquids and microorganisms (e.g., bacteria, fungi, viruses, etc.).
[0013] In many embodiments, the method of the present disclosure includes combining cells with a freezing medium to form a cell mixture, and then placing the cell mixture in the device and apparatus of the present disclosure. In many embodiments, the freezing composition of the present disclosure includes a freezing medium, a freezing agent, and an organic polymer. In many embodiments, the cells are placed in a container prior to freezing, where the container is part of a medical device useful for administering the cells. In such embodiments, the container is configured to withstand very low temperatures and thawing without substantially affecting the viability and sterility of the cells or the function of the device.
[0014] The present disclosure provides compositions, devices and methods for freezing and thawing cells in an appropriate amount for use in treatment after thawing. The treatment cells of the present disclosure have a viability of 50%-100% (i.e., 60-100% of the cells have the ability to grow and divide), are sterile, and can be administered immediately after thawing. In many embodiments, about 50-100% of the cells are retrieved from the container and administered to the patient. In many embodiments, the methods of the present disclosure serve to substantially reduce the rate of loss of closure integrity to less than 20%, less than 10%, less than 5%, or even less. Surprisingly, applicants have found that a polymeric syringe plunger alone is not sufficient to protect the sterility of the compositions of the present disclosure. This is because at very low temperatures such as those disclosed for freezing and storage of the cells of the present disclosure, the plunger allows gas exchange, which can lead to contamination with biological agents such as viruses, fungi, bacteria, and other microorganisms.
[0015] In many embodiments, the compositions, methods and devices of the present disclosure serve to maintain the efficacy of the therapeutic cells of the present disclosure, which may be analyzed by measuring the expression of one or more indicative genes or proteins, such as the production of one or more cytokines, cell cycle markers or extracellular matrix components.
[0016] The present disclosure also provides a method for growing cells to high densities (e.g., about 1.0×10 cells) with or without animal serum while maintaining the viability, identity, and dispersibility of the cells in the composition. 6 cells / ml~5.0×10 8 In some embodiments, the cell density is about 100×10 3 , 0.5×10 6 , 1×10 6 , 1.5×10 6 , 2×10 6 , 3×10 6 , 4×10 6 , 5×10 6 , 6×10 6 , 10×10 6 , 20×10 6 , 30×106 , 40×10 6 , 50×10 6 , 100×10 6 , 200×10 6 , 300×10 6 , 400×10 6 , 500×10 6 , 600×10 6 , or 700×10 6 It is larger than about 750×10 6 , 700×10 6 , 600×10 6 , 500×10 6 , 400×10 6 , 300×10 6 , 200×10 6 , 100×10 6 , 50×10 6 , 40×10 6 , 30×10 6 , 20×10 6 , 10×10 6 , 6×10 6 , 5×10 6 , 4×10 6 , 3×10 6 , 2×10 6 , 1.5×10 6 , 1×10 6 , 0.5×10 6 , or 200×10 3 It may be smaller than
[0017] In most cases, cells for treatment are 0.5×10 6 cells / ml~1.0×10 7 In some embodiments, the density of treatment cells in the cell mixture is about 1.0×10 6 ~9.0×10 6 cells / ml, e.g., about 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, and 8.5 x 10 6cells / ml, approximately 9.0, 8.5, 8.0, 7.5, 7.0, 6.5, 6.0, 5.5, 5.0, 4.5, 4.0, 3.5, 3.4, 3.3, 3.2, 3.1, 3.0, 2.9, 2.8, 2.7, 2.6, 2.5, 2.4, 2.3, 2.2, 2.1, 2.0, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, and 1.1 × 10 6 It can be less than cells / ml.
[0018] The cells may be frozen in one or more dose volumes or amounts. In some embodiments, the doses are about 0.1 ml to 5.0 ml, e.g., about 0.1 ml, 0.2 ml, 0.3 ml, 0.4 ml, 0.5 ml, 0.6 ml, 0.7 ml, 0.8 ml, 0.9 ml, 1.0 ml, 1.1 ml, 1.2 ml, 1.3 ml, 1.4 ml, 1.5 ml, 1.6 ml, 1.7 ml, 1.8 ml, 1.9 ml, 2.0 ml, 2.1 ml, 2.2 ml, 2.3 ml, 2.4 ml, 2.5 ml, 2.6 ml, 2.7 ml, 2.8 ml, 2.9 ml, 3.0 ml, 3.1 ml, 3.2 ml, 3.3 ml, 3.4 ml, 3.5 ml, 3.6 ml, 3.7 ml, 3.8 ml, 3.9 ml, 4.0 ml, or 4. The volume may be greater than 5 ml / dose and less than about 5.0 ml, 4.5 ml, 4.0 ml, 3.9 ml, 3.8 ml, 3.7 ml, 3.6 ml, 3.5 ml, 3.4 ml, 3.3 ml, 3.2 ml, 3.1 ml, 3.0 ml, 2.9 ml, 2.8 ml, 2.7 ml, 2.6 ml, 2.5 ml, 2.4 ml, 2.3 ml, 2.2 ml, 2.1 ml, 2.0 ml, 1.9 ml, 1.8 ml, 1.7 ml, 1.6 ml, 1.5 ml, 1.4 ml, 1.3 ml, 1.2 ml, 1.1 ml, 1.0 ml, 0.9 ml, 0.8 ml, 0.7 ml, 0.6 ml, 0.5 ml, 0.4 ml, 0.3 ml, or 0.2 ml / dose. In some embodiments, one, two, three or more doses may be frozen in one device.
[0019] cell The cells used in the compositions, devices and methods of the present disclosure include mammalian cells, therapeutic cells, e.g., therapeutic human cells. The cells of the present disclosure can be obtained from or administered to various tissues. In many embodiments, the therapeutic cells can be obtained from and administered to intervertebral disc tissue. In many embodiments, various types of cells, e.g., myoblasts, muscle cells, chondrocytes, epithelial cells, osteoclasts, progenitor cells, stem cells, etc., can be obtained from and / or administered to various tissues, including muscle, liver, heart, lung, pancreas, articular cartilage, tendons, ligaments, intervertebral discs, bone, thymus, thyroid, or lymph nodes. In some embodiments, the cells of the present disclosure can be derived from articular cartilage, cardiac tissue, or bone.
[0020] The compositions, devices and methods of the present disclosure are useful for treating a variety of diseases and conditions, including, but not limited to, degenerative disc disease, disc injuries, burns, lacerations, cardiac and muscular injuries, bone fractures / separations, and the like.
[0021] composition In some embodiments, the cells for treatment are harvested from the cell culture medium prior to freezing. In one embodiment, the cells are harvested and pelleted by centrifugation. The pelleted cells can then be resuspended in the freezing composition of the present disclosure to form a cell mixture. In many embodiments, the freezing composition of the present disclosure can include a freezing medium, a freezing agent, and an organic polymer.
[0022] Culture medium The freezing medium (or cryoprotective medium) may contain one or more additives, including, but not limited to, animal serum (e.g., fetal bovine serum (FCS or FBS)) and a cryoprotectant (i.e., a substance that is highly water soluble and has low toxicity). Cryoprotectants added to the freezing medium can promote cell survival by reducing or preventing damage to cells during the freezing and thawing process.
[0023] Various commercially available freezing media can be used to prepare the compositions of the present invention for use in the methods of the present disclosure. For example, in some embodiments, animal serum may not be used, and in such embodiments, "xeno-free" media, such as Profreeze, FreesIS, Cryostor, etc., can be used instead of animal serum-containing media. In various embodiments, the freezing media of the present disclosure can also contain one or more additional components, such as proteins such as albumin. In one embodiment, human, mammalian, or synthetic serum albumin (HSA) can be included in the freezing media. In many embodiments, the amount of freezing media can represent the remaining fraction that does not include the cryoagent and organic polymer. In some embodiments, the amount of the freezing medium is about 60% to about 98.9%, for example, more than about 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, and less than about 100%, 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 8%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81%, 80%, 75%, or 70%. In one embodiment, the amount of the freezing medium is about 91.5%.
[0024] The media of the present disclosure may also contain additional components, such as, for example, amino acids (e.g., glutamine, arginine, or asparagine), vitamins (including, but not limited to, one or more of the B group vitamins, such as vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B7, vitamin B9, or vitamin B12), transition metals (including, but not limited to, nickel, iron (e.g., ferric or ferrous), or zinc), and other media components. The media of the present invention may also be supplemented as needed with hormones and / or other growth factors (e.g., insulin, transferrin, or epidermal growth factor), ions (e.g., sodium, chloride, calcium, magnesium, and phosphate), buffers (e.g., HEPES), nucleosides (e.g., adenosine and thymidine), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. In some aspects, the freezing media of the present invention contain proteins derived from plants or animals. In some embodiments, the freezing medium of the present invention does not contain proteins derived from plants or animals. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art.
[0025] Freezing agent Cryogens (or cryoprotectants) can also be referred to as cryoprotectants. They can be chemicals that help cells maintain viability during the process of freezing and thawing. Cryogens generally enter cells to promote the reduction of intracellular osmotic pressure and the protection of intracellular proteins from denaturation. An example of a cryogen that can pass through cell membranes is DMSO (dimethyl sulfoxide). DMSO can pass through cell membranes, so it can also exit cells after thawing. Other cryogens include glycerol, alginate, polyvinyl alcohol, etc.
[0026] The concentration of the cryoagent used can range from about 1% (by volume or weight) to about 20%. In many embodiments, the concentration of the cryoagent can be, for example, about 7.5% in the case of DMSO. In many embodiments, the concentration of DMSO used can be low to minimize the amount of DMSO administered to the patient treated with the therapeutic cells.
[0027] polymer The frozen composition includes an organic polymer. The organic polymer of the present disclosure is useful for protecting cells during freezing and for serving as a matrix for the therapeutic cells when administered to a patient after thawing. In many embodiments, the organic polymer is a glycosaminoglycan, such as hyaluronic acid, sodium hyaluronate, or hyaluronan. In many embodiments, the concentration of the organic polymer is about 0.1% to 10% by weight of the mixture. In a preferred embodiment, the concentration of the organic polymer is about 1.0%.
[0028] method The cell mixture of the present disclosure can be placed in a suitable container designed to withstand very low temperatures (i.e., less than about -100°C). In some embodiments, the frozen composition can be chilled prior to combination with the cells for treatment. In many embodiments, the cells can be frozen at -20°C to -80°C for 5 to 120 minutes before being subjected to long-term storage. In some embodiments, for long-term storage, the compositions and devices can be stored at about -80°C or about -196°C. For example, the disclosed methods can include freezing cells in a disclosed device at about -20°C, -25°C, -30°C, -35°C, -40°C, -45°C, -50°C, -55°C, -60°C, -65°C, -70°C, -75°C or -80°C for more than about 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 60 minutes, 75 minutes, 90 minutes, 105 minutes, 120 minutes or 180 minutes and less than about 240 minutes, 180 minutes, 120 minutes, 105 minutes, 90 minutes, 75 minutes, 60 minutes, 45 minutes, 40 minutes, 35 minutes, 30 minutes, 25 minutes, 20 minutes or 15 minutes. In many cases, the temperature of the composition may be decreased at a rate of more than about 0.1° C. / min, 0.2° C. / min, 0.3° C. / min, 0.4° C. / min, 0.5° C. / min, 1° C. / min, 2° C. / min, 3° C. / min, 4° C. / min, 5° C. / min, 6° C. / min, 7° C. / min, 8° C. / min, 9° C. / min, or 10° C. / min, and less than about 15° C. / min, 10° C. / min, 9° C. / min, 8° C. / min, 7° C. / min, 6° C. / min, 5° C. / min, 4° C. / min, 3° C. / min, 2° C. / min, 1° C. / min, 0.5° C. / min, 0.4° C. / min, 0.3° C. / min, 0.2° C. / min, or 0.1° C. / min.
[0029] The methods of the present disclosure may involve one-step, multi-step or ramped freezing. In many embodiments, the cells are cryopreserved at about -135°C to about -196°C, e.g., at about -130°C, -135°C, -140°C, -145°C, -150°C, -155°C, -160°C, -165°C, -170°C, -171°C, -172°C, -173°C, -174°C, -175°C, -176°C, -177°C, -178°C, -179°C, -180°C, -181°C, -182°C, -183°C, -184°C, -185°C, -186°C, -187°C, -188°C, -189°C, -190°C, -191°C, -192°C, -193°C, -194°C, -195°C or -196°C. and may be stored in the vapor phase of liquid nitrogen, which may be at temperatures as low as about 196°C, -197°C, -196°C, -195°C, -194°C, -193°C, -192°C, -191°C, -190°C, -189°C, -188°C, -187°C, -186°C, -185°C, -184°C, -183°C, -182°C, -181°C, -180°C, -179°C, -178°C, -177°C, -176°C, -175°C, -174°C, -173°C, -172°C, -171°C, -170°C, -165°C, -160°C, -155°C, -150°C, -145°C, -140°C, and -135°C.
[0030] The cell composition of the present disclosure can be stored for a long period of time.In some embodiments, cells can be stored for more than about 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, 40 weeks, 44 weeks, 48 weeks, 52 weeks, 1 year, 1.5 years, 2 years, 2.5 years, 3 years, 3.5 years, 4 years or more, and for less than about 5 years, 4.5 years, 4 years, 3.5 years, 3 years, 2.5 years, 2 years, 1.5 years, 1 year, 52 weeks, 48 weeks, 44 weeks, 40 weeks, 36 weeks, 32 weeks, 28 weeks, 24 weeks, 20 weeks, 16 weeks, 12 weeks, 10 weeks, 8 weeks or 6 weeks. In many embodiments, the post-thaw viability of stored cells is greater than about 90%, e.g., less than about 100%, 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 80% and 75%, and greater than about 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.
[0031] The cells, compositions and devices may be shipped at a variety of temperatures. In some embodiments, frozen cells may be shipped in a variety of media, including liquid nitrogen, vapor phase nitrogen. In some other embodiments, the methods of the present disclosure may include long-term storage and shipping at temperatures between -80°C and -196°C.
[0032] Prior to freezing, the cells are resuspended in the freezing composition and placed in a container under conditions that maintain the sterility, composition of the mixture, and prevent voids or spaces between the mixture and the container. In some embodiments, the device of the present invention can be pre-loaded with a portion of the composition, and the cells can be added to the composition in the container. In many embodiments, the container is at least a portion of a medical device, such as a syringe barrel, but can be any suitable container for maintaining cell viability at low temperatures. In many embodiments, the container can be useful for administering or applying therapeutic cells directly to a patient. In some embodiments, the container can be implantable and / or biodegradable. In some embodiments, as described in more detail below, the medical device of the present invention can be a container, such as a syringe barrel, that can be capped or sealed to prevent gas exchange between the composition and nitrogen vapor or other gases surrounding the device.
[0033] The methods of the present disclosure may be useful for increasing the rate at which cell temperature is reduced. Increasing the rate of temperature reduction may help to avoid the damaging side effects of freezing (e.g., dehydration) and maintain cell viability. According to the present disclosure, the thawing rate may also be increased over conventional methods. In many embodiments, thawing may be performed by placing the container at room or ambient temperature (e.g., about 20°C to about 25°C) and allowing the cell mixture to reach a liquid form. In some other embodiments, thawing may be performed on ice or using a warming device. In some embodiments, the cell mixture may be brought to a liquid form, i.e., a temperature above about 0° C., in less than about 2 hours, 110 minutes, 100 minutes, 95 minutes, 90 minutes, 85 minutes, 80 minutes, 75 minutes, 70 minutes, 65 minutes, 60 minutes, 55 minutes, 50 minutes, 45 minutes, 40 minutes, 35 minutes, 30 minutes, 25 minutes, or 20 minutes, and more than about 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 60 minutes, 65 minutes, 70 minutes, 75 minutes, 80 minutes, 85 minutes, 90 minutes, 95 minutes, 100 minutes, 105 minutes, 110 minutes, or 115 minutes. In some embodiments, the cell mixture is administered to a patient before the cell mixture reaches body temperature (i.e., about 37°C), i.e., at a temperature lower than about 37°C, 36°C, 35°C, 34°C, 33°C, 32°C, 31°C, 30°C, 29°C, 28°C, 27°C, 26°C, 25°C, or 20°C, and higher than about 15°C, 20°C, 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, 31°C, 32°C, 33°C, 34°C, 35°C, or 36°C.
[0034] Medical Devices The cells can be placed in a medical device or container prior to freezing. In some embodiments, the medical device can be the barrel or lumen of a syringe, and the composition can be enclosed in the barrel with one or more seals, plungers, caps, or other suitable barriers against gas exchange and / or contamination by materials or organisms surrounding the syringe. Cryopreserving, storing, and pumping the cells of the present disclosure in a syringe device can help reduce the cost of manufacturing, shipping, and applying the cells of the present disclosure. For example, using a vial can be more time-consuming and expensive, as the cells need to be transferred to a syringe for application. The use of a syringe can also eliminate the need for the cells of the present disclosure to pass through more than one needle, thus reducing exposure to forces such as shear forces that can affect efficacy. Furthermore, if the cells of the present disclosure are transferred from a storage container to an applicator, loss of sample remaining in the original container can occur. Figure 1 shows one embodiment of a container device of the present disclosure, which is a syringe.
[0035] In FIG. 1, the disclosed device 100 can include a syringe barrel 200, a plunger rod 300, a plunger 400, and a needle end cap 500. An optional barrel cap 600 is also shown. In many embodiments, the syringe may not include a plunger rod. The barrel can have a first plunger end 210, including a barrel flange 215 and a barrel orifice 220 that defines an opening to a barrel lumen 225, and a second needle end 230. The barrel orifice has a diameter d1 and the lumen has a diameter D L5. The barrel flange end may define a substantially flat surface surrounding a barrel orifice having a diameter greater than the outer diameter of the barrel. At or near the needle end may be a needle hub 240, which may define a needle hub lumen 241 defined by an inner surface 242 including a plurality of raised ridges 243 for receiving a cap or luer. Located in the center of the needle hub lumen may be a tip 245 for receiving a needle (not shown) or optionally a needle end cap 500. The tip defines a lumen 250 having a first inlet orifice 251 in fluid communication with the barrel lumen, and a second outlet orifice 252 that may serve to transfer a composition within the barrel lumen to a needle (not shown). The second outlet orifice has a diameter d2 that may be selected to minimize shear forces as the cell composition passes through the tip lumen to a syringe needle (not shown). In various embodiments, the tip lumen may have a constant diameter equal to d2, or may have a varying diameter, with the first inlet orifice defining a diameter smaller than d1 but larger than d2. The tip lumen is generally spaced apart from the barrel lumen inner diameter D, which may be between about 1.0 and 10.0 mm. Lhas an inner diameter smaller than In many embodiments, the barrel lumen has an inner diameter of about 6.0, 6.1, 6.2, 6.3 or 6.4 mm and the tip lumen can have an inner diameter greater than about 0.5 mm, 0.6 mm, 0.7 mm, 0.8 mm, 0.9 mm, 1.0 mm, 1.1 mm, 1.2 mm, 1.3 mm, 1.4 mm, 1.5 mm, 1.6 mm, 1.7 mm, 1.8 mm, 1.9 mm, 2.0 mm, 2.1 mm, 2.2 mm, 2.3 mm or 2.4 mm and less than about 2.5 mm, 2.4 mm, 2.3 mm, 2.2 mm, 2.1 mm, 2.0 mm, 1.9 mm, 1.8 mm, 1.7 mm, 1.6 mm, 1.5 mm, 1.4 mm, 1.3 mm, 1.2 mm, 1.1 mm, 0.9 mm, 0.8 mm, 0.7 mm or 0.6 mm. The tip may also define a length L1 that is greater or less than the length L2 of the needle hub lumen, e.g., less than or greater than about 0.1 mm, 0.2 mm, 0.3 mm, 0.4 mm, 0.5 mm, 0.6 mm, 0.7 mm, 0.8 mm, 0.9 mm, 1.0 mm, 1.1 mm, 1.2 mm, 1.3 mm, 1.4 mm, 1.5 mm, 1.6 mm, 1.7 mm, 1.8 mm, 1.9 mm, 2.0 mm, 2.1 mm, 2.2 mm, 2.3 mm, or 2.4 mm. Thus, the tip may protrude from the needle hub lumen (if the length is greater than the needle hub lumen) or may be recessed (if the length is less than the needle hub lumen). Some embodiments of the disclosed syringes include a needle end cap or needle, while some other embodiments do not. The needle end cap 500 can be configured to securely seal the tip and prevent gas exchange, leakage of cellular compositions from the barrel lumen, and / or ingress of gases, microorganisms, or other foreign matter into the barrel. In the embodiment shown in Figure 1, the needle end cap can have an outer surface 510 defining a plurality of connector ridges 515 that mate with complementary structures on the inner surface of the needle hub lumen. In the embodiment shown in Figure 1, the needle end cap further defines an internal tip lumen 520 that receives the tip on the barrel.
[0036] The plunger rod may be coupled to the plunger in a variety of ways. In one embodiment, for example as shown in FIG. 1, the plunger rod may include a plunger connector 310 at one end and a plunger head 320 at an opposite end. The plunger connector may be configured to fixedly couple to the plunger. In the embodiment shown in FIG. 1, the plunger connector defines threads 315 having a plurality of screw tines 315. The plunger may define a plunger receiver structure 415 for fixedly coupling with the plunger connector on the plunger rod. The embodiment shown in FIG. 1 has a plunger receiver configured as a lumen that receives the plunger connector threads of the plunger rod. The plunger may have an outer surface 420 configured to contact the lumen of the barrel. In the embodiment of FIG. 1, the plunger includes a plurality of ridges 425 on the outer surface.
[0037] Applicant has surprisingly found that polymers cannot maintain an airtight seal within the barrel of a syringe when the syringe is stored at a temperature below about -80°C. In many cases, this failure of polymer plungers is not affected by the plunger rod being removed from the plunger. That is, incomplete sealing is also exhibited in applications where the plunger is fixedly connected to the plunger rod. Applicant has also surprisingly shown that the use of a polymer cap at or near the flange orifice of the barrel can help prevent gas exchange and / or contamination. As shown in Example 2 below, gas exchange / leakage is not prevented by placing an additional plunger in the barrel. Instead, the failure rate can be significantly reduced by sealing the flange end of the barrel. Other methods of sealing the flange end of a syringe include placing other suitable polymer and non-polymer seals at or near the flange end of the barrel. In one embodiment, an adhesive can be placed between the polymer cap and the flat surface of the flange to facilitate sealing, while in other embodiments, other methods known to those skilled in the art can be used to seal the cap to the flat surface.
[0038] FIG. 2 shows an embodiment of the device of the present disclosure configured to maintain closure integrity and reduce contamination of the composition with liquids, gases, microorganisms, or other substances. In this embodiment, the barrel orifice is sealed, at least in part, at the barrel end orifice by placement of a barrel cap 600. In some embodiments, the cap may be held in place by one or more structures or methods to prevent gas exchange and / or ingress of contaminants into the barrel lumen. The barrel cap may be made of any compound or element that can provide a seal against the barrel flange and / or barrel orifice to prevent contamination of the barrel lumen. In some embodiments, additional structures, such as ridges (e.g., as provided on needle end caps), polymer adhesives, metal sealants, etc., may aid in securing the barrel cap.
[0039] The plunger, needle end cap and barrel cap of the present disclosure can be manufactured from a variety of polymeric and non-polymeric materials suitable for use. In some embodiments, the structures can be manufactured from silicone, polypropylene, butyl rubber, natural rubber or other suitable materials. In many embodiments, the barrel lumen, plunger, needle end cap and / or barrel cap can further include a coating, layer or application of a substance, which can help with sealing and friction reduction. In some embodiments, for example, the coating can be silicone, PTFE (polytetrafluoroethylene), or other suitable materials for medical applications well known in the art.
[0040] The medical device of the present disclosure is useful for freezing, storing, thawing and administering therapeutic cells. In many embodiments, the device of the present disclosure includes a body having a first open end and a second open end, and a lumen located between and fluidly connecting the openings. The first open end can define a tip configured to detachably attach and detach a sealing cap or applicator, such as a needle. The tip can define an interior in fluid communication with the lumen, and an exterior. The exterior of the tip can include one or more structures designed to aid in the fixation of the needle, such as a luer lock. In some other embodiments, the cap and needle can be press-fit.
[0041] The second open end may define an opening configured to receive the therapeutic cells of the present disclosure in a frozen composition so that they can be placed in the lumen. The second opening may further be configured to receive a cap, plunger, plug, or other structure designed to fit and movably seal within the wall of the second opening. The wall of the second opening may be continuous with the wall of the lumen. The cap, plunger, plug, or other structure may be designed to be connected (and in some embodiments detachably connected) to a rod portion that may help to apply a force to the cap, plunger, plug, or other structure, thereby moving the cap, plunger, plug, or other structure relative to the lumen wall.
[0042] The devices of the present disclosure are designed to maintain functionality after storage in contact with one or more components of a frozen composition at very low temperatures, for example, a cap, plunger, plug or other structure of the present disclosure, together with the second open end and / or the wall of the lumen, may substantially maintain a fluid seal during freezing, storage and thawing to help prevent contamination of therapeutic cells placed within the lumen.
[0043] The second open end and the wall of the lumen are designed to allow smooth movement of a cap, plunger, plug or other structure thereto while substantially maintaining a fluid seal. In some embodiments, the lumen can include a coating on the wall that can prevent chemical interaction between the device and the freezing composition. In some other embodiments, the composition of the lumen wall can be sufficient to prevent chemical interaction. Chemical interaction can refer to a reaction that can result in a change in either the composition of the device or the freezing composition, which can result in a weakening or change in the treatment effect of the cells and / or the freezing composition.
[0044] The devices of the present disclosure can be manufactured from a variety of materials. In some embodiments, the materials used to manufacture the devices of the present disclosure are resistant to excessive expansion, contraction, breakage, cracking, shattering, etc., upon freezing and thawing. In one embodiment, the devices of the present disclosure can include glass-substitute polymers, such as cyclic olefin polymers (e.g., crystal zenith), or cycloolefin polymers and copolymers. In many embodiments, the devices of the present disclosure can include one or more transparent materials to allow monitoring of the cells and frozen compositions for treatment.
[0045] The luminal walls are sufficiently thin to allow for controlled and rapid freezing and thawing, hi many embodiments, the material of the lumens of the device can be one that can effectively conduct heat to allow for rapid freezing and thawing of therapeutic cells.
[0046] The cap, plug, plunger, or other material may be made, at least in part, of a polymeric compound that resists expansion, contraction, cracking, shattering, etc. upon freezing and thawing. In some embodiments, the polymeric compound comprises one or more organic polymers, such as isoprene or latex. In some embodiments, a lubricant or coating may be applied to the cap, plug, plunger, or other material to help maintain a seal against the lumen wall.
[0047] definition "Medium" and "cell culture medium" refer to a solution for maintaining the viability of eukaryotic cells in culture and in situ (e.g., following administration to a patient in need of such cells). Media of the present disclosure include a nutrient source (e.g., one or more of serum, serum substitutes, glucose, galactose, etc.) utilized for cell growth, and one or more additional components (e.g., hormones, peptides, vitamins, essential amino acids, non-essential amino acids, minerals, salts, buffers, etc.).
[0048] "Freezing medium" can refer to a medium that contains one or more additional components, such as a cryoprotectant, useful for maintaining the viability of eukaryotic cells during and after freezing.
[0049] While several embodiments have been disclosed, further embodiments of the present invention will become apparent to those skilled in the art from the following detailed description. As will be apparent, the present invention is capable of modifications in various obvious aspects without departing from the spirit and scope of the present invention. Accordingly, the detailed description is to be interpreted as illustrative only and not restrictive.
[0050] All references disclosed herein, whether patent or non-patent, are hereby incorporated by reference in their entirety as if recited at the point of reference. In the event of a conflict between a reference and the specification, the specification, including definitions, will control.
[0051] Although the present disclosure has been described with a certain degree of particularity, it will be understood that the disclosure is made by way of example and that changes may be made in detail or structure without departing from the spirit of the present disclosure as defined in the claims. EXAMPLES
[0052] Recovery and viability in frozen compositions The recovery and viability of cells in various media were compared.Cells were frozen in the container device disclosed above and stored in the vapor phase of liquid nitrogen for one month.The container used in this experiment was a syringe system.By storing in the syringe system disclosed herein, the cell mixture can be directly administered to the subject after thawing with minimal manipulation.
[0053] As shown in the bar graph of FIG. 3, good recovery and viability was achieved with all of the freezing compositions tested. EXAMPLES
[0054] Completeness of closure Surprisingly, in early testing, it was found that freezing a sample in a syringe at very low temperatures, such as the temperature of liquid nitrogen vapor, and thawing caused a loss of oxygen in the sample. This indicated that the polymer plunger and / or tip cap were not sufficient to maintain a seal during freezing, storage, and thawing. This failure was seen both when the plunger rod was in place and when it was removed.
[0055] To investigate the cause of this failure, a series of configurations were tested using different syringes and closures. The purpose of this test was to evaluate the container closure integrity (CCI) by non-destructive analysis of the oxygen concentration [%] of the syringe headspace and its total pressure [torr] in multiple syringe configurations stored at very low temperatures. Multiple syringes representing eight different syringe configurations were prepared for this test. The syringes were filled with samples and stored in a very low temperature storage for about 4.5 days. In this condition, a breach of the container closure integrity can result in a decrease in oxygen concentration in the syringe headspace. This decrease in oxygen concentration is believed to be the result of gas leakage and exchange between the nitrogen-rich storage environment and the composition in the syringe.
[0056] As a control, one syringe of each configuration was stored at room temperature in a nitrogen purged airtight cabinet. This negative control sample was designed to examine the effect of very low storage temperatures on gas exchange / leakage.
[0057] Headspace oxygen concentration was measured using tunable diode laser absorption spectroscopy (TDLAS).
[0058] Sample Set Various syringes, plungers and stoppers were combined to test the closure integrity of different configurations (FIG. 4 and Table 1). Seven replicate samples were prepared for the sample formats described in Table 1 below.
[0059] In each replicate, the headspace oxygen concentration and total pressure of each syringe were measured before and after storage.
[0060] [Table 1-1] [Table 1-2] [Table 1-3]
[0061] Methods and Materials Sample preparation and manipulation In this study, PBS was used as the test composition. A Gilson P1000 Pipetman was used to load PBS (Gibco; Cat#: 20012-027; pH 7.2) into each syringe. Care was taken to avoid forming droplets on the inner surface of the syringe barrel. A Dabrico vented placement tool (Dabrico; Cat#: MS-25) was used to insert the designated plunger into the syringe.
[0062] In some sample formats, an additional barrier was provided by the insertion of 081 and 420 stoppers, which were manually inserted into the syringes of sample formats 2 and 7, respectively.
[0063] Sample numbers 1-5 represented the test groups for each sample format. Sample number 6 represented the positive control with a defined defect. The defect in this sample number 6 replicate was created by inserting a syringe needle through the plunger (and stopper, if present) of the syringe. Specifically, a 23 gauge x 1 inch needle was used for all sample formats except sample format 7, which used an 18 gauge x 1.5 inch needle (necessary to penetrate both the plunger and stopper). Sample number 7 for each sample format represented the negative control stored at room temperature in a nitrogen environment, as described above.
[0064] Initial values (T0) of both headspace oxygen concentration and total pressure were measured on the day the sample formats were prepared. On the second day, sample numbers 1-6 of each sample format were placed in a -20°C freezer for 3 hours and then transferred to a -80°C freezer. Sample numbers 1-6 were placed at -80°C for approximately 4 hours and then stored in a Cryoport Express® High Volume Dry Vapor Shipper (all excess liquid nitrogen was removed). The temperature of the dry vapor shipper was monitored using an Apollo IV digital thermometer (UEi; Cat#: DT304) and maintained constant at -177°C (96K) over the approximately 4.5-day frozen storage period. Sample number 7 was stored in an airtight cabinet purged with pure nitrogen and kept at ambient room temperature (approximately 23°C) for approximately 4.5 days.
[0065] After approximately 4.5 days of storage, samples Nos. 1-6 were removed from frozen storage and immediately placed in another nitrogen purged airtight cabinet and allowed to thaw and equilibrate to ambient room temperature (approximately 23° C.) for approximately 2 hours.
[0066] Both headspace oxygen concentration and total pressure at time T1 were measured for all syringes of all formats. Five measurements were made for each sample. A graph showing the change in headspace oxygen concentration from T0 to T1 is shown in Figure 4.
[0067] Headspace oxygen measurement A frequency-modulated tunable diode laser absorption spectroscopy (Lighthouse) was used to measure headspace oxygen in each replicate. This method, called TDLAS, provides a non-invasive and rapid gas analysis of the headspace in a sealed container, giving both the number density of specific gases and the total headspace pressure.
[0068] Prior to the analysis of samples, six oxygen standards of known oxygen concentration were measured five times consecutively to verify the performance of the instrument. Based on the absolute value of the measurement error (the difference between the known value and the measured value) and the measurement precision (the standard deviation of multiple measurements for each standard), the headspace oxygen concentration measurement uncertainty for this study was established as ±0.8% atm.
[0069] Headspace pressure measurement Headspace pressure measurements were performed using an FMS-Moisture / Pressure Headspace Analyzer (Lighthouse) following standard measurement procedures. Briefly, the instrument was turned on and allowed to warm up for at least 30 minutes under a nitrogen purge of at least 1 standard L / min before the measurement session. Calibration was performed using known pressure / humidity standards.
[0070] Prior to sample analysis, known total pressure standards (10 standards for one format and 8 standards for the other format) were measured five times consecutively to verify the performance of the instrument. Based on the absolute value of the measurement error (the difference between the known and measured values) and the measurement precision (the standard deviation of multiple measurements for each standard), the headspace total pressure measurement uncertainty for this study was established as the greater of ±6 torr and ±7% of the measured value.
[0071] result The results of the non-destructive headspace oxygen measurements are summarized in Figure 4. The change in headspace oxygen concentration between time points T0 and T1 is shown for each syringe of the nine different sample formats. The red horizontal line indicates a 3.0% oxygen depletion that was used as a criterion for determining lack of container closure integrity for the syringe (see Discussion section below). The headspace oxygen concentration measurement uncertainty for the standard used in this study was established as ±0.8% atm based on the performance of the oxygen standard. The results of each headspace parameter measured for each syringe sample are summarized in Table 3. The headspace total pressure measurement uncertainty for the sample formats was established as the greater of approximately 6 torr from the measured value or approximately 7% of the measured value based on the performance of the Lighthouse pressure standard.
[0072] [Table 3] TIFF2024167383000004.tif179159 [Table 3 (continued)] TIFF2024167383000005.tif121162
[0073] Discussion and Conclusion Headspace oxygen concentration and total pressure were successfully measured for all syringes in each of the nine configurations (Table 1). The headspace oxygen concentration measurement uncertainty for this study was established as ±0.8% atm based on an oxygen standard. The corresponding measurement uncertainty for total pressure was established as the greater of ±6 torr and ±7% of the measured value based on the performance of the pressure standard. Because the syringes contained liquid water, the headspace was saturated with water vapor, thus giving the maximum FMS signal obtainable in the syringe configuration described.
[0074] The results are summarized in Table 3. The change in headspace oxygen concentration [%] and total pressure [torr] after low-temperature storage is also shown in the table. Under the above conditions, if the container closure integrity is breached in a particular syringe, the oxygen concentration in the headspace may decrease by three possible processes. The first process is that when the temperature decreases, nitrogen vapor around the syringe in the very cold storage may leak into the syringe through the break (defect), thereby diluting the total oxygen in the headspace and decreasing the oxygen concentration. The second process is that the syringe reaches thermal equilibrium at the storage temperature of about 177°C, and then diffusion may occur such that oxygen molecules may leak from the syringe headspace into the nitrogen environment of the very cold storage. The third process is that when the syringe is removed from the very cold storage, the temperature increase in the leaking syringe may create excess pressure in the headspace, which may tend to push out the syringe headspace gas containing the remaining oxygen. It should be noted that if a breach in the container closure integrity reseals upon temperature increase, headspace overpressure may be maintained. The "Plunger Failure" column in Table 3 indicates when the presence of syringe headspace overpressure pushes back the syringe plunger.
[0075] Based on the oxygen change measured in the negative control (sample #7), a drop in headspace oxygen concentration of more than 3.0% was used as the criterion for indicating a container closure failure. Additionally, syringes in which the plunger was pushed back ("plunger failure") due to an increase in syringe temperature were also considered to have a container closure failure. Finally, a headspace pressure increase of more than 100 torr was defined as an additional criterion that a loss of CCI had occurred.
[0076] The results for the individual syringes, shown in Figure 4 and Table 3, indicate that 29 of the 45 syringe samples stored at low temperature lost container closure. As expected, all eight of the positive controls (sample no. 6) also failed the criteria.
[0077] All five replicates lost CCI for sample formats 1, 4, 5, and 8, and four of the five test syringes for sample format 3. Each of these formats used only a plunger to seal the syringe barrel. Interestingly, sample format 8 contained two plungers. Sample format 7, which contained a stopper at the end of the barrel, was the most effective at preventing CCI loss.
Claims
1. Freezing medium; Freezing agent; and Organic Polymers 13. A pharmaceutical composition for maintaining the viability of mammalian cells for treatment comprising:
2. 2. The pharmaceutical composition of claim 1, wherein the freezing agent comprises dimethylsulfoxide.
3. 3. The pharmaceutical composition of claim 1 or 2, wherein the freezing medium is free of animal serum.
4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the polymer is hyaluronic acid.
5. The pharmaceutical composition according to any one of claims 1 to 4, wherein the cells are derived from intervertebral disc tissue, skin, muscle, intestine, bone marrow, nerve, liver, heart, lung, pancreas, articular cartilage, bone, thymus, thyroid or lymphatic tissue.
6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the cells are derived from intervertebral disc tissue, articular cartilage, cardiac tissue or bone.
7. 1. A device for freezing and thawing a cell mixture for treatment, comprising: A container comprising: a first open end having a first diameter; a second open end having a second diameter smaller than the first diameter; a lumen including a lumen wall having a lumen diameter similar to the first diameter and in fluid communication with the first and second open ends; a container comprising: a first polymer seal configured to be fitted within the lumen and provide sealing contact with a lumen wall; a first polymer cap designed to seal the first open end; and A second polymeric cap designed to seal the second open end.
8. 8. The container of claim 7, wherein the container defines a syringe barrel and the first polymeric seal is a piston or plunger.
9. 9. The container of claim 7 or 8, wherein the container is made of a transparent polymer.
10. The container according to any one of claims 7 to 9, wherein the container is made of a cyclic olefin polymer.
11. The container of any of claims 7 to 10, wherein the second open end defines a luer lock capable of receiving a syringe needle of suitable construction when the second polymeric cap is removed.
12. 1. A method of freezing mammalian cells for treatment, comprising: combining a plurality of therapeutic cells and the composition to form a mixture; placing the mixture into a container of a medical device having a first opening and a second opening; placing a first polymer seal in contact with the mixture; disposing a first polymer cap in the first opening and a second polymer cap in the second opening to form a hermetic seal; reducing the temperature of the mixture to −80° C. or below; Maintaining said mixture at a temperature below −80° C. for at least 30 days; wherein after 30 days at least about 50% of said cells have grown and divided at least once in cell culture.
13. 13. The method of claim 12, wherein the mixture is maintained in the vapor phase of liquid nitrogen at less than about -130°C or for at least a portion of the 30 day period.
14. 14. The method of claim 12 or 13, wherein after 30 days at least about 90% of the cells have grown and divided at least once.
15. The method according to any of claims 12 to 14, wherein after maintaining the cells, the mixture is thawed to a liquid form at a temperature of about 20 to 40°C.
16. The method according to any one of claims 12 to 15, wherein the therapeutic cells are derived from human intervertebral disc tissue.
17. The container comprises: a first open end having a first diameter; a second open end having a second diameter; a lumen including a lumen wall in fluid communication with the first and second open ends; 17. The method of any of claims 12-16, wherein the container is fabricated from one or more biocompatible materials that maintain their structural integrity when frozen at below about -130°C and thawed.
18. The method of any of claims 12 to 17, wherein the device prevents exchange of at least nitrogen gas when the device is stored at a temperature below -80°C.
19. The method of any of claims 12 to 18, wherein the cells are derived from intervertebral disc tissue, skin, muscle, intestine, bone marrow, nerve, liver, heart, lung, pancreas, articular cartilage, bone, thymus, thyroid or lymphatic tissue.
20. The pharmaceutical composition according to any one of claims 12 to 19, wherein the cells are derived from intervertebral disc tissue, articular cartilage, cardiac tissue or bone.
Citation Information
Patent Citations
Composition for cryopreservation of nucleated cell
JP2000201672A
Syringe
JP2004033442A
cryopreservation medium
JP2007530052A
Methods and compositions for improving the viability of cryopreserved cells
JP2012533620A
A tip cap and an injection device having a distal tip sealed by the tip cap
JP2016524981A
